Transformable liquid-metal nanomedicine by Wang, Chao et al.
ARTICLE
Received 11 May 2015 | Accepted 29 Oct 2015 | Published 2 Dec 2015
Transformable liquid-metal nanomedicine
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To date, numerous inorganic nanocarriers have been explored for drug delivery systems
(DDSs). However, the clinical application of inorganic formulations has often been hindered
by their toxicity and failure to biodegrade. We describe here a transformable liquid-metal
nanomedicine, based on a core–shell nanosphere composed of a liquid-phase eutectic
gallium-indium core and a thiolated polymeric shell. This formulation can be simply produced
through a sonication-mediated method with bioconjugation flexibility. The resulting
nanoparticles loaded with doxorubicin (Dox) have an average diameter of 107 nm and
demonstrate the capability to fuse and subsequently degrade under a mildly acidic condition,
which facilitates release of Dox in acidic endosomes after cellular internalization. Equipped
with hyaluronic acid, a tumour-targeting ligand, this formulation displays enhanced
chemotherapeutic inhibition towards the xenograft tumour-bearing mice. This liquid metal-
based DDS with fusible and degradable behaviour under physiological conditions provides a
new strategy for engineering theranostic agents with low toxicity.
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T
he engineering flexibility provided by inorganic nano-
particles with tailorable shape, size, surface ligands and
physical properties has enabled on-demand design of novel
drug delivery systems, contrast agents and integrated systems for
disease diagnosis and treatment1–6. The last decade has witnessed
numerous efforts in developing inorganic nanoparticles capable
of effectively targeting different diseases7–11. However, these
formulations often fail to be useable due to systemic toxicity. For
instance, targeted cancer therapy requires nanoparticles with
relatively large sizes to minimize clearance12 and enhance tumour
retention13,14, yet such inorganic particles often remain in the
body for a long time because of their lack of biodegradability.
To date, few studies have demonstrated how to engineer the
physicochemical properties of inorganic nanoparticles to satisfy
both target delivery and efficient elimination15,16. This design
bottleneck has long existed and is impeding the clinical
translation of therapy and diagnostics based on inorganic carriers.
We report here a novel liquid metal-based nanoscale formula-
tion for drug delivery to achieve enhanced anticancer therapy.
Taking advantage of the unique characteristics of a eutectic alloy
of gallium indium (EGaIn, 75% Ga and 25% In by weight), this
novel nanomedicine has a variety of merits in terms of simple
fabrication, facile surface bioconjugation and the capability of
fusion and degradation in a mildly acidic environment. EGaIn is a
low-viscosity liquid at room temperature. Unlike Hg, it has low
toxicity and has thus attracted considerable attention for
applications of microfluidic systems, soft robotics and stretchable
electronics17–19. To obtain EGaIn-based drug nanocarriers,
an emulsion-like ligand-mediated procedure is simply applied
through ultrasonication at room temperature. During
sonication20, the thiolated ligands readily assemble onto the
surface of the EGaIn, competing with the oxidation process
and facilitating control of the particle size17,20–22. The two
ligands used here, thiolated (2-hydroxypropyl)-b-cyclodextrin
(designated MUA-CD) and thiolated hyaluronic acid (designated
m-HA), not only serve as capping agents during the formation of
nanoscaled liquid-metal spheres but also play roles of drug-
loading matrix and active targeting moiety, respectively. The final
formulation (designated LM-NP/L) comprises three primary
functional constituents: a CD-based drug-loading motif, the
targeting ligand HA and an EGaIn core. The seven-membered
sugar ring of the CD provides faithful loading sites for
doxorubicin (Dox)23, a model broad-spectrum chemothera-
peutic drug. The HA moiety supports active tumour targeting
towards the receptors including the CD44 receptor, which is
overexpressed on the cell surface of a broad variety of tumours,
including human cervical cancer and breast cancer24. After
intravenous injection, LM-NP/L is expected to accumulate at
tumour sites as a result of passive25 and active targeting effects.
Upon endocytosis, the LM-NPs/L are expected to fuse with each
other in the mildly acidic endosome microenvironment26, leading
to the dissociation of Dox-containing ligands and therefore
promote drug release. The aggregates of fused LM-NPs/L are
expected to degrade due to the synergistic effect of oxidative
corrosion. Furthermore, the main degradation product, Ga (III),
can serve as anticancer agent itself to reverse drug resistance
in drug-resistant cancer cells27,28. Taken together, this liquid
metal-based nanomedicine is transformable: (1) it can be simply
generated from a bulk material; (2) fusion happens to promote
drug release in an acidic cellular environment; and (3) it can be
biodegraded to reverse drug resistance and avoid potential
systemic toxicity.
Results
Preparation of transformable liquid-metal nanomedicine.
To prepare the liquid metal nanocarriers, EGaIn was added to a
centrifuge tube filled with an ethanolic solution of thiolate CD
and thiolate HA (volume ratio of EGaIn: ethanol¼ 1:150,
Fig. 1a,b,e). After sonication, the largest particles precipitated
within seconds, and the nanoscale colloids was removed from the
tube and resuspended in water (Fig. 2a). Next, Dox-loaded LM-
NP/L (LM-NP/Dox-L) was obtained by overnight incubation
with triethanolamine-treated Dox. The mixture was washed to
remove the excess Dox. The resulting LM-NP/Dox-L appeared as
core–shell structured nanospheres with a diameter of B107 nm,
which was consistent with the results determined by dynamic
light scattering tests (Fig. 2b). The Dox-loading capacity could be
tuned by adjusting the ratio between MUA-CD and m-HA. In a
typical formulation used in the following investigations, the
Dox-loading capacity was determined as 24% (Dox weight ratio
of the total weight of nanoparticles). Interestingly, the addition of
m-HA could significantly decrease the average particle size of
product as well as enhance the systemic stability, which could
be attributed to the negative charge of the anionic m-HA
(Supplementary Table 1).
To study the acid-triggered conformational transformation and
subsequently promoted drug release, the release profile of Dox
from LM-NP/Dox-L (Fig. 2c) under neutral (1 PBS buffer,
pH 7.4) and acidic (1 PBS buffer, pH 5.0) conditions were
investigated through the dialysis method29. A burst release of
loaded Dox was clearly observed within the first 30 min in the
acidic buffer, significantly different from the release curve
recorded in the neutral buffer. Similarly, paclitaxel (PTX),
which shows insignificant solubility change in the pH range of
2.5–8 (ref. 30), was loaded to LM-NP/L as a model drug. As
expected, the release profile of LM-NP/L loaded with PTX also
presented a high release rate within the first 30 min in the acidic
buffer (Supplementary Fig. 4). The acidic buffer caused 72% of
the loaded PTX to release within 4 h, which was significantly
higher than the 28% in the neutral environment. Dox-loaded gold
nanoparticles (GNPs/Dox) with an average diameter of 100 nm,
where Dox was included into the MUA-CD ligands with the same
Dox-loading capacity as LM-NP/Dox-L, were also applied as a
control. Compared with GNP/Dox, LM-NP/Dox-L displayed
a more potent acid-promoted Dox release at pH 5.0
(Supplementary Fig. 5). This phenomenon could be attributed
to fusion of LM-NP/L triggered by the disruption of the oxidized
shell of LM-NP/L, and the subsequent dissociation of surface
ligands. Next, the conformational change of LM-NP/Dox-L with
up to 4 h acid treatment (pH 5.0) was visualized using
transmission electron microscopy (TEM) imaging (Fig. 2d). The
initial fusion behaviour was captured within the first 5 min after
acid treatment, and the aggregates formed by fusion increased in
size over time. These results were in good agreement with the
significant increase in size distribution upon acid treatment as
measured by dynamic laser scattering (Fig. 2e). We hypothesized
that the acid attacked the oxidized layer20 on the surface of the
LM-NP/L to trigger fusion of LM-NP/L (Supplementary Figs 8,9;
Fig. 2f), which further led to the fusion of the liquid inner cores31.
Furthermore, the degradation of LM-NP/Dox-L at pH 5.0 was
clearly observed via the optical microscope (Fig. 2g) and TEM
imaging (Fig. 2d) over time; while negligible difference was
observed in the case of neutral buffer. The representative TEM
image of LM-NPs/Dox-L immersed in acidic (pH 5.0) PBS buffer
for 72 h showed evidence of degradation into the hollow
polymeric shells dotted with shrunk metallic cores in the inner
wall evidenced the occurrence of degradation. To further verify
the degradation of LM-NPs, the change of Ga (III) ion
concentration in PBS buffer over time was monitored by the
inductively coupled plasma optical emission spectrometry. The
Ga (III) concentration in the acidic buffer displayed a notable
increase over time; while the degradation of LM-NPs in neutral
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solution was moderate (Fig. 2f). The degradation process of
LM-NPs was then tracked and quantified by monitoring the
change of light transmittance over time (Fig. 2h). The light
transmittance of acidic LM-NP solution increased from 25 to
66%, which was in good agreement of the proposed degradation
of LM-NPs in acidic environment. Of note, the main degradation
product, Ga (III) ion, has been reported to reverse drug resistance
in drug-resistant cancer cells27,28, which could potentially
generate synergistic effects and prevent drug resistance.
Furthermore, the nature of the EGaIn metal core and the
verified acid-triggered fusion might also open the possibility of
utilizing these transformable nanospheres for imaging contrast
enhancement. After acid treatment (12 h in 1 PBS buffer,
pH 5.0), the homogeneous contrast enhancement caused by
LM-NPs was disrupted, replaced by heterogeneous contrast
within the imaged area with higher contrast at the locations of
fused particles and lower contrast at spots in absence of LM-NPs
(Fig. 2i). The resulting changes in contrast were quantified by
studying the grey value profiles of representative areas in X-ray
images (Fig. 2i). The grey values of the imaging area were
approximately constant before acid treatment, indicating homo-
geneous imaging contrast. The disruptions of the homogeneous
imaging contrast after acid treatment were supported by the
appearance of peaks in the grey value plot. Similar fusion of
LM-NPs accumulated at tumour site would potentially lead to
enhanced contrast of tumour tissue during X-ray imaging.
Intracellular acid-triggered fusion and promoted Dox release.
The intracellular delivery of LM-NP/Dox-L into HeLa cells was
further explored using the confocal laser scanning microscopy
(Fig. 3a). The fluorescence of Dox was clearly observed in HeLa
cells after 1 h of incubation with LM-NP/Dox-L, indicating the
cellular internalization of the nanospheres. When the incubation
time was prolonged to 4 h, Dox was highly localized within the
nuclei of HeLa cells, as indicated by the magenta fluorescence
(Fig. 3a). The cellular uptake of LM-NP/Dox-L displayed an
energy-dependent manner, and LM-NP/Dox-L mainly entered
HeLa cells via macropinocytosis (Supplementary Fig. 10).
Next, the endocytosis process of LM-NP/Dox-L was also
















































































Figure 1 | Schematic design of the transformable liquid-metal delivery system. (a) Preparation route of LM-NP/Dox-L. (b) The main components of
LM-NP/Dox-L: thiolated CD with Dox, HA-based targeting motif and an EGaIn core. (c) pH-responsive delivery of Dox by LM-NP/Dox-L to the nuclei
for the targeted cancer therapy. (I) accumulation of LM-NP/Dox-L at the tumour site through passive and active targeting; (II) specific binding to the
overexpressed receptors on the tumour cells; (III) receptor-mediated endocytosis; (IV) acid-triggered fusion of LM-NP/Dox-L and endosomal/lysosomal
escape of Dox-containing ligands; (V) accumulation of Dox in the nucleus. (d) Acid-triggered fusion and degradation process of LM-NP/Dox-L.
(e) Chemical structures of MUA-CD and m-HA.
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treated with LM-NP/Dox-L for different time durations. After 1 h
incubation, fusion of LM-NPs was clearly observed in the acidic
endosomes, agreeing with the in vitro results discussed above.
After 4 h incubation, more fusion events of LM-NPs were spotted,
together with few single LM-NPs dispersed in the cytosol.
Furthermore, we quantified and visualized the fusion process
intracellularly by lysing the cells incubated with LM-NPs/Dox-L
at different incubation time points. The intracellular Ga/In ion
concentrations were then quantified by inductively coupled
plasma mass spectrometry. Importantly, the structures formed
via fusion were also further validated using TEM and analysed
with the titan scanning/TEM at an atomic scale. Similar to the
LM-NPs/Dox-L treated with acid (Fig. 2d), the initial fusion
behaviour was captured immediately upon cellular uptake,
followed by the formation of larger aggregates and the eventual
degradation, which was in good agreement with the significant
increase of intracellular Ga (III) ion concentration over incuba-
tion time (Supplementary Fig. 1). The element mapping results
revealed the fusion of the polymeric shells during the
conformational changes of LM-NP/L (Fig. 3c). The scattering of
























































































































Figure 2 | Characterization of liquid-metal nanospheres. (a) EGaIn was ultrasonically dispersed in ligand containing ethanol mixture (shown schematically
in Fig. 1a). (b) The hydrodynamic size of LM-NP/Dox-L measured by dynamic light scattering. Inset: TEM image of LM-NP/Dox-L. Scale bar, 100 nm. (c) The
release profiles of LM-NP/Dox-L at different pH levels. (d) Representative TEM images of LM-NP/Dox-L after different time immersed in acidic (pH 5.0) PBS
buffer. Scale bars, 100 nm (for 5 min); 100 nm (for 1 h); 100 nm (for 4 h); 400 nm (for 72 h). (e) Polydispersity index (PDI) of LM-NP/Dox-L immersed in
neutral (pH 7.4) and acidic (pH 5.0) PBS buffer. (f) Changes of metal ion concentration under neutral and acidic environments. (g) Optical images of
LM-NPs before and after acid treatment. Scale bar, 40mm. (h) Light transmittance change over time. (i) X-ray images (left) of LM-NPs immersed in neutral
(pH 7.4) and acidic (pH 5.0) PBS buffer (particles were imaged after 12 h treatment). The images were taken in a 96-well plate. Red lines indicate the areas
quantitatively analysed. Grey value analysis (right) of representative area in X-ray images of LM-NPs. Error bars indicated s.d. (n¼ 3).
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Figure 3 | Intracellular interaction and drug release. (a) Intracellular delivery of LM-NP/Dox-L towards HeLa cells at different time points observed by
confocal laser scanning microscopy. The cells were incubated with LM-NP/Dox-L at 37 C for 1 and 4 h, respectively. The late endosomes and lysosomes
were stained with LysoTracker Green, and the nuclei were stained with Hoechst 33342. Scale bar, 10mm. (b) Representative TEM images of HeLa cells
incubated with LM-NP/Dox-L for 1 and 4 h. Red arrows show fused nanospheres; green arrows show dispersion of single nanosphere in the cytosol.
Scale bar, 2 mm. (c) Element mapping results of intracellular LM-NPs/Dox-L collected from HeLa cells after different incubation times. Scale bars, 100 nm
(for 5 min); 100 nm (for 1 h); 100 nm (for 4 h); 200 nm (for 24 h). (d) Flow cytometric analysis of HeLa cell apoptosis induced by LM-NP/Dox-L for 12 h
using the Annexin V-FITC/4,6-diamidino-2-phenylindole (DAPI) staining. (e) HeLa cell apoptosis induced by LM-NP/Dox-L for 20 h using the APO-BrdU
TUNEL assay. (f) In vitro cytotoxicity of LM-NP/Dox and LM-NP/Dox-L on HeLa cells for 24 h. Error bars indicate s.d. (n¼4). Note: the concentration of
LM-NP/L is equal to the nanocarrier concentration of Dox-loaded formulations in each corresponding group; the error bars in f (group LM-NP/Dox-L at
concentrations 1.25, 2.5 and 5 mg l 1) are small. (g) In vitro cytotoxicity of LM-NP/Dox-L on Dox-resistant HeLa cells for 24 h. Error bars indicate s.d.
(n¼4). Note: the concentration of LM-NP/L is equal to the nanocarrier concentration of Dox-loaded formulations in each corresponding group. *Po0.05,
**Po0.01 compared with the Dox solution group (two-tailed Student’s t-test).
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Ga signal after 5-min incubation indicated the fast disruption
of the oxidized shell. After 1 h of incubation, the increase of S and
O signals in the background suggested the dissociation of thio-
lated surface ligands. The time-of-flight secondary ion mass
spectrometry was further utilized to analyse the surface of LM-
NP/L and intracellular LM-NP/L collected by lysing the cells
internalized with particles (Supplementary Fig. 2). The coex-
istence of thiols and oxides was well evidenced by the overlap of
the signals of GaO and GaS in LM-NP/L. The increase of
HS signal in the background after 5 min incubation visualized
the dissociation of thiolated surface ligands, indicating the initial
stage of fusion behaviour. The remarkable increase in the back-
ground HS signal and the significant decreases in the signals of
GaO and GaS clearly indicated that the intracellular fusion
behaviour of LM-NP/L was a result of the synergistic action
of the dissociation of thiolated surface ligands and the disruption
of oxides.
The Annexin V-FITC/4,6-diamidino-2-phenylindole apoptosis
detection and the terminal deoxynucleotidyl transferase dUTP
nick end labelling (TUNEL) assay were performed to compare
the apoptosis-inducing capabilities of LM-NP/Dox-L and free
Dox solution. Annexin V-FITC labels the phosphatidylserine
translocated to the extracellular membrane upon the initiation of
apoptosis32, while 4,6-diamidino-2-phenylindole has significantly
higher staining efficiency with cells where the plasma membrane
integrity has been compromised33. This combination allows the
differentiation among the early apoptotic cells, the late apoptotic
cells and the viable cells, which can be quantitatively determined
by the flow cytometry. The total apoptotic ratio of HeLa cells
incubated with LM-NP/Dox-L was 68%, which was significantly
higher than 43% of HeLa cells incubated with LM-NP/Dox
(Fig. 3d). In addition, the cells treated with LM-NP/Dox-L
showed extensive apoptotic DNA fragmentation stained by the
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Figure 4 | Tumour targetability and antitumour activity. (a) In vivo fluorescence imaging of the HeLa tumour-bearing nude mice at 6, 24 and 48 h after
intravenous injection of Cy5.5-(LM-NP/Dox) (I) and Cy5.5-(LM-NP/Dox-L) (II) at Cy5.5 dose of 30 nmol kg 1. Arrows indicate the sites of tumours.
(b) Ex vivo fluorescence imaging of the tumour and normal tissues collected from the HeLa tumour-bearing nude mice being killed at 48 h post injection.
The numeric label for each organ is as follows: 1, heart; 2, liver; 3, spleen; 4, lung; 5, kidney; 6, tumour. (c) Region-of-interest analysis of fluorescent signals
from the tumours and normal tissues. Error bars indicated s.d. (n¼ 3). *Po0.05 (two-tailed Student’s t-test). (d) The HeLa tumour growth curves after
intravenous injection of different formulations of Dox at a dose of 2 mg kg 1. Error bars indicate s.d. (n¼ 5). *Po0.05, **Po0.01 (two-tailed Student’s
t-test). (e) The body weight variation of HeLa tumour-bearing mice during treatment. Error bars indicate s.d. (n¼ 5). (f) Representative images of the HeLa
xenograft tumours of the mice after treatment with the studied Dox formulations at day 14. The numeric label for each mouse is as follows: 1, saline; 2, Dox;
3, LM-NP/Dox; 4, LM-NP/Dox-L. Arrows indicate the sites of tumours. (g) Representative images of HeLa xenograft tumours collected from the mice after
treatment with different formulations at day 14. The numeric label for each tumour is as follows: 1, saline; 2, Dox; 3, LM-NP/Dox; 4, LM-NP/Dox-L. Scale
bar, 1 cm. (h) Histological observation of the tumour tissues after treatment. The tumour sections were stained with haematoxylin and eosin (H&E). Scale
bar, 100 mm. (i) Detection of apoptosis in the tumour tissues after treatment. The tumour sections were stained with fluorescein-dUTP (green) for
apoptosis and Hoechst for the nuclei (blue). Scale bar, 50mm.
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that LM-NP/Dox-L is an effective intracellular delivery vehicle for
enhanced apoptosis-inducing activity.
Next, the cytotoxicity of Dox-loaded nanospheres towards
HeLa cells was evaluated with 3-(4, 5-dimethylthiazol-2-yl)-2,
5-diphenyltetrazolium bromide assay (Fig. 3f). Cell viability was
dependent on both Dox concentration and incubation time,
as expected. The half-maximal inhibitory concentration (IC50)
of LM-NP/Dox and LM-NP/Dox-L towards HeLa cells for
24 h treatment were 0.81 and 0.23 mg l 1, respectively.
LM-NP/Dox-L displayed higher cytotoxicity than free Dox
solution (IC50¼ 1.33 mg l 1), while blank LM-NPs/L without
Dox showed insignificant cytotoxicity within the range of
tested concentrations. At low Dox concentration (0.16 and
0.31 mg l 1), LM-NP/Dox also had higher cytotoxicity than free
Dox solution. It was suggested that the acid-promoted release of
Dox achieved by liquid metal nanospheres provided higher
cytotoxic activity towards cancer cells. It should be noted
that LM-NP/Dox-L showed significantly enhanced cytotoxicity
(3.5-fold for 24 h treatment) compared with LM-NP/Dox towards
HeLa cells that overexpress CD44 receptor34, which can be
attributed to the HA-targeting moiety.
We further investigated in vitro cytotoxicity of
LM-NP/Dox-L towards Dox-resistant HeLa cells. The results
showed that LM-NP/Dox-L displayed significant cytotoxicity
towards Dox-resistant HeLa cells (IC50¼ 2.46 mg l 1), while free
Dox solution did not show any obvious cytotoxicity even at
the concentration of 5 mg l 1 (Fig. 3g). This result is encouraging
and offers guideline for future applications of LM-NPs in the
combination treatment of cancer drug resistance.
Tumour targeting and antitumour efficacy of LM-NP/Dox-L.
To evaluate the tumour-targeting capability of LM-NP/Dox-L
(Fig. 1c,d), Cy5.5-labelled LM-NP/Dox-L (Cy5.5-(LM-NP/Dox-L))
was administrated intravenously into the HeLa tumour-bearing
mice. Within a short time period, Cy5.5-(LM-NP/Dox-L) pre-
sented a stronger fluorescence signal in the tumour region com-
pared with Cy5.5-labelled LM-NP/Dox (Cy5.5-(LM-NP/Dox))
without the HA-targeting moiety (Fig. 4a). As time increased,
elevated fluorescence signals of Cy5.5-(LM-NP/Dox-L) were
observed at the tumour site as compared with the normal tissues
within 48 h post injection, indicating a notable tumour-targeting
effect of the nanospheres. After 48 h post injection, the mice were
killed, and the tumours as well as normal tissues were collected
for ex vivo imaging study. The intensity of fluorescence signal of
Cy5.5-(LM-NP/Dox-L) at tumour site was significantly higher
than that of Cy5.5-(LM-NP/Dox) (Fig. 4b). On the basis of the
quantitative region-of-interest analysis, the fluorescence intensity
of Cy5.5-(LM-NP/Dox-L) at the tumour site was 1.82-fold that
of Cy5.5-(LM-NP/Dox) (Fig. 4c). In addition, the fluorescence
signal at the tumour site was three times higher than that in the
liver or kidney (Fig. 4b,c). The potent tumour-targeting capability
of LM-NP/Dox-L can be attributed to the combination of an
enhanced permeability and retention effect and active targeting
mechanisms.
The time-dependent biodistribution of LM-NPs/L was further
quantified by inductively coupled plasma mass spectrometry.
HeLa tumour-bearing nude mice were killed at 6, 24 and
48 h after intravenous injection of LM-NPs/Dox-L for tissue
collection. The results further substantiated the potent tumour-
targeting capability of LM-NPs/Dox-L (Supplementary Fig. 11).
The pharmacokinetics of LM-NP/Dox-L administered intrave-
nously into mice was evaluated by quantitatively monitoring the
Dox concentration in blood plasma (Supplementary Fig. 12). The
elimination half-life (t1/2), the mean residence time and the area
under the curve depicting the plasma drug concentration versus
time were significantly higher than those of the free Dox solution,
suggesting the capability of LM-NP/Dox-L to maintain a high
drug concentration during a prolonged systemic circulation. The
antitumour efficacy of LM-NP/Dox-L was further assessed in the
HeLa tumour-bearing xenograft mice. Different Dox formula-
tions displayed significant tumour inhibition effects compared
with saline as a negative control after successive intravenous
administration into the HeLa tumour-bearing mice (Fig. 4d, f, g).
Both LM-NP/Dox and LM-NP/Dox-L displayed remarkably
higher inhibition efficacy towards HeLa tumour growth than
the free Dox solution, which primarily resulted from the tumour-
targeting capability of these nanospheres. More importantly,
a noticeable difference in tumour volume inhibition between
LM-NP/Dox-L and LM-NP/Dox was observed (Fig. 4d,f,g),
further demonstrating the enhanced active targeting capability
of LM-NP/Dox-L. No significant change of mice body weights
was observed during the treatment of LM-NP/Dox-L (Fig. 4e).
The histological images using haematoxylin and eosin staining
showed that a massive cancer cell remission occurred in the
tumour tissue (Fig. 4h) after LM-NP/Dox-L administration,
with no obvious pathological abnormalities in normal organs,
including cardiomyopathy, the major toxic effect of Dox cancer
treatment (Supplementary Fig. 13)35. Moreover, the images
obtained using the in situ TUNEL assay showed the highest
level of cell apoptosis in the tumour collected from the mice
treated with LM-NP/Dox-L (Fig. 4i), indicating that the supreme
tumour inhibition activity was attributable in part to the
increased apoptosis induced by LM-NP/Dox-L. The anticancer
behaviour of LM-NPs/L was also explored in tumour-bearing
mice, where no significant anticancer effects were observed after
intravenous injection of blank LM-NPs/L (Supplementary
Fig. 14). Collectively, these results verified that HA-conjugated
LM-NP/Dox-L efficiently accumulated at the tumour site,
indicating effective receptor-mediated intracellular transport,
and thereby achieved the optimal antitumour efficancy in vivo.
Toxicology evaluation of LM-NP/Dox-L. The toxicology of
LM-NP/L to female Balb/c mice was investigated over 3 months
(Fig. 5). The female Balb/c mice injected with LM-NP/L
(45 mg kg 1) were killed at 3, 7, 20, 40 and 90 days post injection
for blood collection. The levels of important liver function
markers, including the alanine aminotransferase, aspartate
aminotransferase, alkaline phosphatase and the albumin con-
centration were all within reference ranges36,37, indicating that no
obvious hepatic toxicity was induced by LM-NP/L treatment
(Fig. 5a,b). As an indicator of the kidney functions, the urea levels
in the blood of treated mice were also within the normal range
(Fig. 5c). For the haematological assessment, we selected white
blood cells, red blood cells, haemoglobin, mean corpuscular
volume, mean corpuscular haemoglobin, mean corpuscular
haemoglobin concentration, platelet count and haematocrit
(Fig. 5d–k). Although a vibration of platelets concentration was
observed on day 3, the value itself still fell into a reference normal
range36. In addition, a steady recovery in platelets level was
observed over time. The platelets level fully recovered on day 20,
with no significant difference compared with that of the age
control group. All of the above indices in the LM-NP/L-treated
groups were normal compared with the control groups. We also
performed necropsy of the sacrificed mice, and no noticeable
organ damage was observed (Fig. 5l). Tissues collected from the
heart, brain and muscle were also investigated, and no obvious
tissue injury was observed (Supplementary Fig. 15). Taken
together, we concluded that LM-NP/L displayed no obvious
toxicity at the treatment dose, which was highly encouraging for
the application of LM-NP/L as nanomedicine.
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Figure 5 | Toxicology evaluation. Blood biochemistry and haematology data of female Balb/c mice treated with LM-NPs/L at the dose of 45 mg kg 1 (total
nanocarrier dose used in antitumuor efficacy study) at 3, 7, 20, 40 and 90 d: (a) alanine aminotransferase (ALT), alkaline phosphatase (ALP) and aspartate
aminotransferase (AST) levels in the blood at different time points after LM-NPs/L treatment. (b,c) Time-course changes of albumin concentration and
blood urea nitrogen (BUN). (d-k) Time-course changes of white blood cells (d), red blood cells (e), platelets (f), haemoglobin (g), mean corpuscular
volume (h), mean corpuscular haemoglobin (i), mean corpuscular haemoglobin concentration (j) and haematocrit (k) from control mice (CK) and
LM-NPs/L-treated mice. Error bars indicate s.d. (n¼ 3). (l) Histology evaluation of the major organs (liver, spleen and kidney) collected from the control
untreated mice and LM-NPs/L-injected mice at different time points post injection. Scale bars, 100 mm. d, days.
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The single-dose, acute toxicity of LM-NP/L and LM-NP/Dox-L
to female Balb/c mice was investigated by identifying the
maximum tolerated dose (MTD). The estimated MTD of
LM-NP/L was determined to be 700 mg kg 1, suggesting low
acute toxicity. The estimated MTD of LM-NP/Dox-L was found
to be 55 mg kg 1 (Dox dose), 1.75-fold higher than that of free
Dox solution. In addition, no obvious increase in IgE production
was observed in LM-NP/L-injected mice, revealing no sign of
allergic reactions (Supplementary Fig. 16).
Moreover, we have also monitored the time-dependent
excretion to study the in vivo metabolism of LM-NPs/L
(Supplementary Fig. 17). The results suggested that the clearance
of LM-NPs/L was possibly through both fecal and renal
excretions. The excreted concentrations of both gallium and
indium were steadily decreased over time.
Discussion
We have developed a new liquid metal-based drug delivery
platform for anticancer therapy. The formulation can be easily
formed and tailored via ligand-mediated self-assembly using
facile ultrasonication. The resulting liquid-metal nanospheres are
able to fuse for promoting drug release and eventually degrade
under a mild acidic environment. After fusing, these nanospheres
also display a contrast enhancing capability when imaged by
X-ray, suggesting potential as a theranostic reagent. Systematic
investigation of toxicology of LM-NP/L revealed no obvious
toxicity at the treatment dose, favouring its biomedical applica-
tions. Although there were no obvious signs of toxicity in these
studies, we will further evaluate the systemic toxicity of the
developed formulations, as well as other promising candidates
made from different liquid metal, such as pure gallium. Moreover,
considering other physical properties of liquid metal, including
capability of dissolving iron or other metals, mechanical flexibility
towards tissues and electrical conductivity, many new materials
and scaffolds integrated with liquid metal for drug delivery and
tissue engineering can be envisioned.
Methods
Materials. All chemicals were purchased from Sigma-Aldrich (St Louis, MO,
USA) unless otherwise stated. Thiol–polyethylene glycol–amine (HS-PEG-NH2)
with the PEG molecular weight of 1,000 was purchased from Sigma-Aldrich and
Nanocs Inc. (New York, NY, USA). Dox hydrochloride was purchased from
BIOTANG Inc. (Lexington, MA, USA).
Preparation and characterization. For a typical LM-NP/L preparation, a small
amount of EGaIn (80 ml) was added to a centrifuge tube (50 ml), which was filled to
a total volume of 12 ml with ethanol containing 4 mg thiolate CD and 0.5 mg
thiolate HA. After sonication, the largest particles precipitated within seconds, and
the slurry was removed from the vial. The remained solution was further purified
by mild centrifugation (1,000 r.p.m.) to remove relatively large particles. The
resulting nanospheres were collected via centrifugation and resuspended in PBS
buffer. To prepare LM-NP, EGaIn (80 ml) was added to a centrifuge tube (50 ml),
which was filled to a total volume of 12 ml with ethanol containing 4 mg thiolate
CD. After sonication, the largest particles precipitated within seconds, and the
slurry was removed from the vial. The remained solution was further purified by
mild centrifugation (1,000 r.p.m.) to remove relatively large particles. The resulting
nanospheres were collected via centrifugation and resuspended in PBS buffer.
Cy5.5-labelled nanospheres were prepared by adding Cy5.5-conjugated
HS-PEG-NH2 (molecular weight: 1,000) into the ethanol containing mixture. For
loading of Dox, 1 ml of LM-NP/L was incubated with 100ml of triethanolamine-
treated Dox in dimethyl sulfoxide (5 mg ml 1) with stirring at room temperature
overnight. The resulting Dox-loaded LM-NP/L was extensively washed with
PBS via centrifugation to remove the excess Dox. LM-NP/Dox, LM-NP/Rho
and LM-NP/Rho-L were prepared following the same procedure. For TEM
characterization, LM-NP/Dox was cast onto a TEM copper grid (300 mesh;
Ted Pella). After drying in air, the sample was observed by TEM (JEM-2000FX,
Hitachi) operating at 200 kV.
In vitro acid-triggered Dox and PTX release. LM-NP/Dox and LM-NP/Dox-L
(0.5 ml) were added into a dialysis tube (10K MWCO; Slide-A-Lyzer, Thermo
Scientific) and dialysed against 14 ml of the PBS buffer solution at pH 5.0 or 7.4,
and gently shaken at 37 C in a shaker (New Brunswick Scientific) at 100 r.p.m.
At predetermined time intervals, the total buffer solution was replaced with 14 ml
of fresh buffer solution with the same pH. The fluorescence intensity of Dox
released was measured at 596 nm with an excitation wavelength of 480 nm using a
microplate reader (Infinite M200 PRO, Tecan). PTX release study was conducted
following the same procedure. The concentration of PTX was determined by
high-performance liquid chromatography (Hewlett Packard 1100).
Cell culture. HeLa cells were obtained from Tissue Culture Facility of UNC
Lineberger Comprehensive Cancer Center and cultured in DMEM with 10% (v:v)
fetal bovine serum, 100 U ml l penicillin and 100 mg ml l streptomycin in an
incubator (Thermo Scientific) at 37 C under an atmosphere of 5% CO2 and 90%
relative humidity. The cells were sub-cultivated approximately every 3 days at 80%
confluence using 0.25% (w:v) trypsin at a split ratio of 1:5.
Intracellular trafficking. HeLa cells (1 105 cells per well) were seeded in a
confocal microscopy dish (MatTek). After culture for 24 h, the cells were incubated
with LM-NP/Dox-L (2mM Dox concentration) at 37 C for 1 h and 4 h, respec-
tively, and then washed twice using PBS at 4 C. Subsequently, the cells were
stained with LyosTracker Green (50 nM) (Life Technologies) at 37 C for 30 min
and Hoechst 33342 (1 mg ml 1; Life Technologies) at 37 C for 10 min. Finally, the
cells were washed using PBS twice at 4 C and immediately observed using confocal
laser scanning microscopy (LSM 710, Zeiss).
In vitro cytotoxicity. HeLa cells (1 104 cells per well) were seeded in the 96-well
plates. After culture for 24 h, the cells were exposed to the Dox solution and
Dox-loaded LM-NPs with different concentrations of Dox for 24 h, followed by
adding 20ml of the 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide
solution (5 mg ml l). After 4 h of incubation, the medium was removed, and the
cells were mixed with 150 ml of dimethyl sulphoxide. The absorbance was measured
at a test wavelength of 570 nm and a reference wavelength of 630 nm by a
microplate reader (Infinite M200 PRO, Tecan).
Apoptosis assay. Apoptosis of HeLa cells was detected using the APO-BrdU
TUNEL Assay Kit (Life Technologies) and Annexin V-FITC Apoptosis Detection
Kit (BD Biosciences). The cells (1 105 cells per well) were seeded in the six-well
plates. After culture for 48 h, the cells were incubated with Dox-loaded LM-NPs
for 12 h (Annexin V-FITC) or 20 h (TUNEL). The subsequent procedures were
performed in accordance with the manufacturer’s protocol. For Annexin V-FITC
apoptosis detection, the cells were analysed by flow cytometry (BD FACSCalibur),
while for the TUNEL assay the cells were observed by fluorescence microscope
(IX71, Olympus).
Animals and tumour xenograft models. All animals were treated in accordance
with the Guide for Care and Use of Laboratory Animals, approved by the
Institutional Animal Care and Use Committee (IACUC) of North Carolina State
University. To set-up the tumour xenograft model, the female nude mice (6 weeks,
J:NU, The Jackson Laboratory) were subcutaneously inoculated in the back with
1 107 HeLa cells. The tumour size was monitored by a vernier caliper and the
tumour volume (V) was calculated as V¼ LW2/2, where L and W were the
length and width of the tumour, respectively.
In vivo imaging study. The animal study protocol was approved by the
Institutional Animal Care and Use Committee at North Carolina State University
and University of North Carolina at Chapel Hill. When the tumours reached to
200–400 mm3, the mice were intravenously injected by Cy5.5-(LM-NP/Dox) and
Cy5.5-(LM-NP/Dox-L) at Cy5.5 dose of 30 nmol kg 1. Images were taken on the
IVIS Lumina imaging system (Caliper, USA) at 6, 24 and 48 h post injection29.
After the 48-h scanning, the mice were killed. The tumours as well as major organs
were collected, weighed and subjected for ex vivo imaging. Region-of-interests were
circled around the organs, and the fluorescence intensities were analysed by Living
Image Software.
In vivo antitumour efficacy. The tumour-bearing mice were weighed and
randomly divided into different groups when the tumour volume reached to
50 mm3. From day 0, the mice were intravenously injected with Dox solution
(2 mg kg 1), LM-NP/Dox (2 mg kg 1), LM-NP/Dox-L (2 mg kg 1) and saline as
a negative control every other day for 12 days, and meanwhile the tumour size was
measured. At day 14, the mice were killed, and the tumour as well as the heart were
collected, weighed, washed with saline thrice and fixed in the 10% neutral-buffered
formalin. For the haematoxylin and eosin staining, the formalin-fixed tumours and
hearts were embedded in paraffin blocks and visualized by optical microscope
(DM5500B, Leica). For the TUNEL apoptosis staining, the fixed tumour sections
were stained by the In Situ Cell Death Detection Kit (Roche Applied Science)
according to the manufacturer’s protocol. Hoechst 33342 was used for nuclear
counterstaining. The stained tumour slides were observed by fluorescence
microscope (IX71, Olympus).
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